This retrospective cohort study of 462 consecutive adult allogeneic and autologous blood or marrow transplantation (BMT) patients compared the incidence of hepatic veno-occlusive disease (VOD) after BMT with three prophylactic regimens. Patients receiving heparin (Hep), heparin + prostaglandin E1 (Hep + PGE1) or low molecular weight heparin (LMWH) as a prophylactic VOD regimen were compared to a historical cohort receiving no VOD prophylaxis. Of 462 BMT patients, VOD was diagnosed in 22% (31 of 142) of the no prophylaxis group, 11% (11 of 104) of the Hep, 12% (13 of 110) in the Hep + PGE1 and 4% (four of 106) of the LMWH group (P = 0.0002). VOD was the primary cause of death in 20% (12 of 59). By multivariate logistic regression, independent risk factors for developing VOD were: no VOD prophylactic regimen, unrelated allogeneic BMT, Karnofsky performance score (KPS) Ͻ80 and aspartate aminotransferase (AST) у50 U/l. There was no increase in the rate of death due to hemorrhagic events or VOD in any prophylaxis group compared to the control group. Prospective randomized trials of Hep vs LMWH vs placebo are warranted to assess the efficacy of heparin compounds in the prevention of VOD. Bone Marrow Transplantation (2001) 27, 627-633. Keywords: veno-occlusive disease; prophylaxis; heparin; blood and marrow transplantation Veno-occlusive disease (VOD) of the liver is a clinical syndrome, characterized by hyperbilirubinemia, painful hepatomegaly and fluid retention.
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. 2, 3 Diagnostic criteria for VOD have been previously described by McDonald et al 1, 2, 4 and Jones et al. 3 The etiology of VOD is not clearly defined, however, drug-induced hepatocellular damage occurs in the centrilobular zones of the liver. The coagulation cascade may have a role in VOD pathophysiology due to clotting factor activation leading to fibrin deposition in the central veins. It has been postulated that anticoagulant therapy could prevent fibrin deposition and subsequent hepatic damage. 5, 6 Several clinical trials of prophylactic heparin (Hep) during BMT have shown contradictory results. [7] [8] [9] [10] [11] [12] Nevertheless, these studies demonstrated that low doses of Hep could be safely administered to BMT patients. Prostaglandin E1 (PGE1) was used as a VOD prophylactic regimen by Gluckman et al, 13 who found a decreased incidence of VOD in patients treated with PGE1, whereas Bearman et al, 14 concluded that PGE1 was too toxic. Previous work has demonstrated the efficacy and safety of low molecular weight heparin (LMWH) for deep venous thrombosis prophylaxis and treatment. 15, 16 A small prospective study comparing LMWH to placebo revealed a shorter duration of VOD-related symptoms after BMT in the LMWH treated patients. 17 In our retrospective study, we analyzed three VOD prophylactic regimens in 462 patients undergoing allogeneic or autologous BMT. The VOD preventive effects of Hep, Hep + PGE1 and LMWH were compared to each other and to a historical control group. This is the first retrospective multivariate analysis of three prophylactic regimens used in one patient population.
Patients and methods

Study design
This retrospective cohort study included all adult patients (у18 years old) who underwent autologous or allogeneic BMT between 1991 and 1997. Patients received VOD prophylaxis consisting of (a) None (1991-1997), (b) Hep (1994 Hep ( -1997 , (c) Hep + PGE1 (1994-1997) or (d) LMWH (1996) (1997) . The Hep and Hep + PGE1 treated patients were part of a randomized phase II study, 18 the remaining data were based on retrospective analysis. The no VOD prophylaxis group was primarily a historical cohort of patients transplanted before initiation of the VOD prophylactic regimens. During 1996-1997, patients were either enrolled on the randomized phase II study or given LMWH based on the discretion of the treating physician and patient refusal to participate in the randomized study. Our study does not include patients treated after 1997 because of major changes in BMT conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive care that may have affected VOD incidence.
Study population
Four hundred and sixty-two consecutive adult patients underwent allogeneic (n = 216) or autologous (n = 246) BMT at Roswell Park Cancer Institute from 1991 to 1997 for the treatment of leukemia (n = 169/462 = 37%), lymphoma (n = 159/462 = 34%), breast cancer (n = 83/462 = 18%), multiple myeloma (n = 36/462 = 8%) and other hematologic disorders or selected solid tumors (n = 15/462 = 3%).
Diagnosis of VOD
VOD was defined according to previously published criteria as the onset of two of the following occurring before day 30 post-BMT: (a) jaundice (total serum bilirubin Ͼ2 mg/dl), (b) hepatomegaly and right upper abdominal pain, (c) ascites and/or unexplained weight gain. 1 No other identifiable cause for liver disease including infection or GVHD could be present.
Prophylactic regimen administration
Patients in the randomized study received Hep 5 U/kg/h i.v. continuous infusion 12-24 h prior to the start of their myeloablative regimen, keeping the daily PTT р50. If the PTT was Ͼ50, the Hep was adjusted daily until a PTT of р50 was obtained. PGE1 was started a minimum of 12 h prior to conditioning therapy and was given via continuous infusion at a rate of 0.1-0.4 g/kg/h depending on patient tolerance. Therapy with Hep ± PGE1 was continued until day 30 or day of discharge with a minimum treatment of 15 days post BMT. In the LMWH group, 30 mg enoxaparin was administered subcutaneously twice a day within 24 h of initiation of the conditioning regimen and continued until day of discharge or day 28 post BMT.
BMT conditioning regimens
The conditioning regimens included: (1) (9) thiotepa and cyclophosphamide. 19 All regimens, except 7 and 9, were used for autologous and allogeneic BMT (7 for allogeneic and 9 for autologous BMT only). No pharmacokinetic measurements were performed during any of the conditioning regimens. All timepoints were calculated from the day of the infusion of blood or bone marrow (day 0).
Donor types and GVHD prophylaxis
Allogeneic BMT patients received bone marrow, peripheral blood or cord blood from related or unrelated donors. Allogeneic BMT patients received GVHD prophylaxis with (1) cyclosporine and methotrexate; 25 (2) cyclosporine and methylprednisolone;
26 (3) cyclosporine, OKT3 and methylprednisolone; 27 (4) cyclosporine, methotrexate and methylprednisolone; 28 or (5) FK506 (tacrolimus) and methotrexate. 29 FK506 was substituted if the patient exhibited cyclosporine toxicity. Two syngeneic BMT patients analyzed with the allogeneic group received no GHVD prophylaxis. Acute GVHD was treated with high dose methylprednisolone from 2-10 mg/kg/day and cyclosporine 2-4 mg/kg/day. Grade I GVHD was treated with topical steroids only.
Other BMT supportive care
Autologous and allogeneic BMT patients received antimicrobial prophylaxis with fluconazole (or ketoconazole prior to 1995) and acyclovir. All patients received acyclovir prophylaxis from day 0 to day of discharge for a minimum of 21 days. In addition, allogeneic BMT patients received ganciclovir prophylaxis from day 30 to day 100 following BMT if the donor or recipient were positive for cytomegalovirus. Autologous BMT patients with TBI-or carmustinecontaining regimens and all allogeneic BMT patients received intravenous immunoglobulin (IVIG) infection prophylaxis beginning on day −1 at a dose of 500 mg/kg then weekly × 8 doses, then biweekly × 4 doses. Acute GVHD was classified according to published criteria; after day 100, chronic GVHD was graded according to published criteria. 30, 31 Statistical analysis VOD was evaluated as a binary endpoint. Univariate analysis used the Fisher's exact test or analysis of variance (ANOVA) where appropriate (SPSS v7.5, Chicago, IL, USA). To determine VOD risk factors, forward stepwise logistic regression models were used conditional on the Wald score with each variable having a P value Ͻ0.1 to enter and Ͼ0.1 to remove. For each significant variable in the model, 95% confidence intervals of the relative risk estimates were calculated. To adjust for multiple comparisons, statistical significance was considered at P Ͻ 0.01. P values between 0.01 and 0.10 were considered as trends toward an association and are presented in the Tables.
Results
Study patients
Of the 462 BMT patients, 246 underwent autologous and 216 allogeneic BMT. One hundred and forty-two patients did not receive any VOD prophylaxis either because they underwent BMT between 1991 and 1993 (n = 127) when no prophylaxis was routinely used, or between 1994 and 1997 (n = 15) if they were (a) at low risk for VOD; (b) at high risk for hemorrhagic complications; or (c) refused prophylaxis. One hundred and four patients received Hep and 110 patients received Hep + PGE1 as part of a phase II study. 18 One hundred and six patients received LMWH during 1996 and 1997. Table 1 summarizes the patient characteristics for all 6 (4) 8 (8) 8 (7) 14 (13) Breast cancer, n (%)
33 (23) 17 (16) 19 (17) 14 (13) Other, n (%)
8 (6) 3 (3) 3 (3) 1 (1) BMT regimen b Bu-containing, n (%) 17 (12) 9 (9) 17 (15) 
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patients by prophylactic regimen. Although this was not a randomized study, most patient characteristics were similar between VOD prophylactic groups. There was no significant difference with regard to age, gender, diagnosis, TBI, pre-transplant aspartate aminotransferase (AST) level, or BMT type (autologous vs allogeneic) with a trend toward statistical significance for Karnofsky performance score (KPS) (P = 0.05) and donor type (autologous vs related allogeneic vs unrelated allogeneic, P = 0.04). The no prophylaxis group had the lowest proportion of unrelated allogeneic BMT; the Hep group had the highest proportion of unrelated allogeneic BMT patients; the Hep + PGE1 and LMWH groups had similar proportions of unrelated allogeneic BMT patients. There was a significant difference between VOD prophylactic regimens with respect to BMT conditioning regimen, stem cell source and GVHD prophylaxis. These variables were considered in the univariate and multivariate analyses. Table 2 shows the incidence of VOD by prophylactic regimen in all BMT patients. Of 462 BMT patients, VOD was diagnosed in: (a) 31 cases (22%) in the no prophylaxis group; (b) 11 cases (11%) in the Hep group; (c) 13 cases (12%) in the Hep + PEG1 group; and (d) four cases (4%) in the LMWH group (P = 0.0002). Since heparin compounds can increase the risk of hemorrhage, we examined the rate of death due to hemorrhagic events (diffuse alveolar hemorrhage, gastrointestinal bleeding, or central nervous system hemorrhage) for each VOD prophylactic group and found no significant difference in the rate of primary cause of death due to a hemorrhagic event (P Ͼ 0.1). Table 3 summarizes the patient characteristics that were tested for an association with developing VOD. Age, gender, time from diagnosis to BMT, busulfan and thiotepa containing conditioning regimens, methotrexate-or OKT3-containing GVHD prophylaxis and time to neutrophil and platelet engraftment were not significantly different between patients who did and did not develop VOD. A significantly higher proportion of patients who developed VOD had an allogeneic BMT (P = 0.0002), a related or unrelated donor (P = 0.0007), stem cells derived from bone marrow (P = 0.0019), no VOD prophylaxis (P = 0.0002), and a KPS Ͻ80 (P = 0.003). There was a trend toward a significant difference with a diagnosis of leukemia (P = 0.05), conditioning with etoposide, cytoxan and TBI (VCT, P = 0.04), TBI-containing regimens (P = 0.06), and median pretransplant AST (P = 0.02).
VOD incidence by prophylactic regimen
Univariate analysis of VOD incidence
Multivariate analysis of risk factors for VOD
The following factors were considered in the multivariate logistic regression model: diagnosis (leukemia vs lym- Table 2 Incidence of VOD and cause of death due to VOD and hemorrhage by prophylactic regimen in all BMT patients
No prophylaxis Heparin
VOD, n (%) 31 (22) 11 (11) 13 (12) 4 (4) 59 (13) 0.0002 Primary cause of death, VOD, n (%)
8 (6) 1 (1) 1 (1) 2 (2) 12 (3) NS Primary cause of death, HEM, n (%)
5 (4) 3 (3) 3 (3) 1 (1) 12 (3) NS VOD = veno-occlusive disease; BMT = blood or marrow transplant; PGE1 = prostaglandin E1; LMWH = low molecular weight heparin; HEM = hemorrhage. a NS, not significant, P Ͼ 0.1.
phoma vs myeloma vs breast cancer vs other), time from diagnosis to BMT (continuous), KPS (у 80 vs Ͻ80), conditioning regimen (busulfan-containing vs thiotepa-containing vs VCT vs other), donor type (autologous vs related allogeneic vs unrelated allogeneic), stem cell type (BM vs PB vs BM + PB vs CB), methotrexate-containing GVHD prophylaxis, OKT3-containing GVHD prophylaxis, VOD prophylaxis (LMWH vs Hep ± PGE1 vs None) and pretransplant AST (elevated vs normal). Table 4 summarizes the variables that were significant predictors of VOD. The data shown evaluate AST as a dichotomous variable (elevated vs normal AST). Substituting AST as a continuous variable in the same model results in the same independent predictors and a finding that for every increase in AST by 10 U/l, there is a corresponding increase in risk of developing VOD of 16.5% (95% confidence interval 1.0-32.4%, P = 0.04).
Since none of the autologous BMT patients received cyclosporine as part of the GVHD prophylaxis regimen, we were unable to differentiate the effect of cyclosporine vs donor type as predictive of developing VOD. The increasing use of PB and decreasing use of BM as the stem cell source over time yielded a difference in the proportion of each by VOD prophylactic regimen in the univariate analysis, however, stem cell type was not shown to be an independent risk factor for developing VOD in the multivariate analysis.
Treatment of VOD
Of the 59 patients who developed VOD, nine patients received tissue plasminogen activator (tPA) 32 and 39 received tPA + PGE1 as therapy for VOD. Eleven had close observation and no drug therapy after developing VOD. In addition, 26 of the 403 patients who did not develop VOD were treated with PGE1 for suspected VOD (ie transient bilirubin elevation). Of the 48 patients who were treated with tPA Ϯ PGE1 for VOD, three (6%) died of hemorrhagic events (one from each VOD prophylaxis group: LMWH, Hep, Hep + PGE1). The use of tPA Ϯ PGE1 for VOD therapy was not associated with an increased risk of hemorrhagic death in any prophylaxis group.
Rate of death due to VOD in the VOD cases by prophylactic regimen
Overall, 20% (12 of 59) of VOD cases died of VOD as the primary cause of death. There was no statistically signifi- Median time to platelet Ͼ20 000/ml (days) 69 28 NS NS = P Ͼ 0.1; BMT = blood or marrow transplant; Hep = heparin; PGE1 = prostaglandin E1; LMWH = low molecular weight heparin; Bu = busulfan; Tt = thiotepa; TBI = total body irradiation; VCT = etoposide, cytoxan, TBI; ANC = absolute neutrophil count; BM = bone marrow; PB = peripheral blood; GVHD = graft-versus-host disease. AST Ͻ50 U/l 1.0 AST у50 U/l 3.7 (1.4-9.9) 0.01 VOD = veno-occlusive disease; RR = relative risk estimate; CI = confidence interval; LMWH = low molecular weight heparin; Hep = heparin; PGE1 = prostaglandin E1; BMT = blood or marrow transplant; KPS = Karnofsky performance score; AST = aspartate aminotransferase. a Multivariate analysis is based on 407 patients with complete data; 55 patients were excluded based on missing data on KPS and/or AST. b Factors that were not significant in the model: months from diagnosis to BMT, diagnosis, conditioning regimen, methotrexate-containing GVHD prophylaxis; OKT3-containing GVHD prophylaxis and stem cell source.
Discussion
Given the severity and incidence of VOD and the lack of effective treatment, pursuit of prophylaxis is important. This and previous studies used very low doses of heparin for VOD prophylaxis because of the risk of bleeding. LMWH can be safely given at higher doses with a lower risk of hemorrhagic complications. Thus, the LMWH doses used in this study potentially had a higher prophylactic effect than unfractionated heparin with or without PGE1. Despite the heterogeneity of conditioning regimens, patient characteristics, and GVHD prophylaxis, the VOD incidence was significantly decreased with all of the prophylactic regimens. The greatest decrease was seen in the LMWH group. Although our study was not randomized, we found a similar incidence of VOD in the no prophylaxis group as several other studies. 1, 3, 7, 8, 10, 13 We confirmed previous findings that unrelated donor, decreased performance status and elevated AST are significant risk factors for developing VOD. We concluded that a significantly lower incidence of VOD developed in patients treated with Hep Ϯ PGE1 or LMWH than in the control patients. We also found that LMWH was more effective than unfractionated heparin; PGE1 had no additional benefit.
The encouraging results of our study justify the role of Hep and LMWH in the prophylaxis of VOD, however prospective randomized trials should verify the superior efficacy and low risk of hemorrhagic complications of LMWH in preventing VOD after BMT.
